CEMIPLIMAB + Gemcitabine + MOTIXAFORTIDE + NAB-PACLITAXEL for adenocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Sep 2020: Trial registered, NCT04543071
  2. 9 Nov 2020: Trial started, NCT04543071

The trials

NCT04543071: Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

State
Under way
Phase
Phase 2
People
118 planned
Started
9 Nov 2020
Primary completion
Jun 2028
Arms
Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel
Results
None posted
  1. 9 Sep 2020: Trial registered
  2. 9 Nov 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.